This Research Topic focuses on cancer informatics and is intended to present and discuss innovative reports, methodologies, tools, and algorithms that enable precision cancer medicine related to genomics, proteomics, and metabolomics (“omics”) data being generated on clinical tumors. These omics data in combination with approaches, tools and algorithms have the potential to transform cancer care through high-throughput analysis of patient-derived tumors and promote “precision” medicine through tumor molecular profiling.

The association of preterm or low birth weight (LBW) with the risk of metabolic syndrome is still unclear. This study aimed to assess the association between preterm or LBW and metabolic syndrome risk according to study or participants' characteristics. PubMed, Web of Science, and EMBASE were searched for epidemiologic studies on the association published up to April 30, 2020. Pooled odds ratio (ORs) and weighted mean differences (WMDs) with 95% confidence intervals (CIs) were calculated using the random-effects model. Low birth weight was associated with an increased risk of metabolic syndrome (OR, 1.37; 95% CI, 1.17–1.61). In the subgroup analysis by study design, the pooled ORs for LBW and metabolic syndrome in the cohort and cross-sectional studies were 1.79 and 1.22. In the subgroup analysis by sex, LBW was found to be associated with an increased risk of metabolic syndrome in pooled studies including both men and women or studies including only women. The association between premature birth and risk of metabolic syndrome was significant in cohort studies (OR, 1.72; 95% CI, 1.12–2.65). Also, LBW or preterm was significantly associated with a higher Homeostasis Model Assessment of Insulin Resistance (WMD, 0.28; 95% CI, 0.19–0.36). Low birth weight and preterm might be risk factors for metabolic syndrome.